NCT07900438
A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Time to first occurrence of a composite endpoint consisting of: Onset of persistent reduction of ≥ 50% in eGFR compared with baseline, Onset of persistent eGFR < 15 mL/min/1.73 m^2, Initiation of chronic kidney replacement therapy, Kidney death, CV death
Timeframe: From Baseline (Week 0) up to Week 169
Secondary (9)
Change in estimated glomerular filtration rate (eGFR) (creatinine CKDEPI, 2009)
Change in eGFR (creatinine CKDEPI, 2012)
Change in eGFR (cystatin C-creatinine CKD-EPI, 2021)
Relative change in Urine Albumin-to-Creatinine Ratio (UACR)
Time to all-cause death
Show 4 moreShow less
Time to first occurrence of composite MACE endpoint consisting of Non-fatal myocardial infarction, Non-fatal stroke & CV death
Change in glycated haemoglobin (HbA1c)
Number of serious adverse events
Number of severe hypoglycaemic episodes
Arms and interventions
SemaglutideExperimental
Participants will receive subcutaneous injection of semaglutide once weekly.
Drugs: Semaglutide
Sites
26 sites in 1 country